Chicago Capital LLC Grows Stock Position in Pfizer Inc. (NYSE:PFE)

Chicago Capital LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 0.9% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 75,895 shares of the biopharmaceutical company’s stock after acquiring an additional 698 shares during the quarter. Chicago Capital LLC’s holdings in Pfizer were worth $2,196,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in PFE. Los Angeles Capital Management LLC increased its position in Pfizer by 59.6% in the first quarter. Los Angeles Capital Management LLC now owns 47,663 shares of the biopharmaceutical company’s stock worth $1,323,000 after buying an additional 17,799 shares in the last quarter. Douglas Lane & Associates LLC increased its holdings in Pfizer by 1.5% in the 1st quarter. Douglas Lane & Associates LLC now owns 46,677 shares of the biopharmaceutical company’s stock worth $1,295,000 after acquiring an additional 704 shares in the last quarter. RDA Financial Network raised its stake in Pfizer by 8.0% during the 1st quarter. RDA Financial Network now owns 12,938 shares of the biopharmaceutical company’s stock worth $359,000 after acquiring an additional 960 shares during the period. Game Plan Financial Advisors LLC lifted its holdings in Pfizer by 1,671.4% during the first quarter. Game Plan Financial Advisors LLC now owns 3,100 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 2,925 shares in the last quarter. Finally, Northwest Investment Counselors LLC bought a new position in shares of Pfizer in the first quarter worth approximately $89,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Pfizer stock opened at $29.22 on Friday. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The company has a market cap of $165.58 billion, a price-to-earnings ratio of -487.00, a PEG ratio of 1.02 and a beta of 0.67. The firm’s fifty day moving average is $29.07 and its 200 day moving average is $28.44. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the firm earned $0.67 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 5.75%. Pfizer’s payout ratio is presently -2,800.00%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Thursday, October 3rd. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. UBS Group increased their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday. They set a “market perform” rating and a $32.00 price objective for the company. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.